Sanara MedTech/$SMTI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sanara MedTech
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
Ticker
$SMTI
Sector
Primary listing
Employees
108
Headquarters
Website
Sanara MedTech Metrics
BasicAdvanced
$167m
-
-$4.36
1.05
-
Price and volume
Market cap
$167m
Beta
1.05
52-week high
$35.95
52-week low
$16.05
Average daily volume
60k
Financial strength
Current ratio
1.801
Quick ratio
1.534
Long term debt to equity
806.77
Total debt to equity
812.727
Interest coverage (TTM)
1.35%
Profitability
EBITDA (TTM)
11.808
Gross margin (TTM)
92.71%
Net profit margin (TTM)
-36.43%
Operating margin (TTM)
8.87%
Revenue per employee (TTM)
$950,000
Management effectiveness
Return on assets (TTM)
7.10%
Return on equity (TTM)
-1.75%
Valuation
Price to revenue (TTM)
1.522
Price to book
27.42
Price to tangible book (TTM)
-9.99
Price to free cash flow (TTM)
73.421
Free cash flow yield (TTM)
1.36%
Free cash flow per share (TTM)
0.248
Growth
Revenue change (TTM)
18.97%
Earnings per share change (TTM)
282.41%
3-year revenue growth (CAGR)
31.02%
10-year revenue growth (CAGR)
40.78%
3-year earnings per share growth (CAGR)
63.17%
10-year earnings per share growth (CAGR)
11.20%
What the Analysts think about Sanara MedTech
Analyst ratings (Buy, Hold, Sell) for Sanara MedTech stock.
Sanara MedTech Financial Performance
Revenues and expenses
Sanara MedTech Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sanara MedTech stock?
Sanara MedTech (SMTI) has a market cap of $167M as of May 01, 2026.
What is the P/E ratio for Sanara MedTech stock?
The price to earnings (P/E) ratio for Sanara MedTech (SMTI) stock is 0 as of May 01, 2026.
Does Sanara MedTech stock pay dividends?
No, Sanara MedTech (SMTI) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Sanara MedTech dividend payment date?
Sanara MedTech (SMTI) stock does not pay dividends to its shareholders.
What is the beta indicator for Sanara MedTech?
Sanara MedTech (SMTI) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.